Privia Health Group, Inc.
NASDAQ:PRVAMedical - Healthcare Information Services
+$0.15 today
- Market cap
- $3.14B
- Beta
- 0.87
- P/E (TTM)
- 134.4
- EPS (TTM)
- $0.18
Volume 2.38M
Average 0.95M
PRVA Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Privia Health Group, Inc.NASDAQ: PRVA
Accounts Receivables · Q2 FY2026 · quarter ended Jun 2026
Accounts receivables grows, but more slowly than its trailing trend
Q2 FY2026 accounts receivables of $59.6M (cash outflow) rose 21.8% year over year, behind the +41.1% change in trailing-twelve-month accounts receivables. Sequentially, it fell 47.1% from the prior quarter. Over 3 fiscal years it compounded at -20.2% a year.
Context
- Accounts receivables amounted to 1.7% of revenue in FY2025, up 0.6 pp from a year earlier.
- Accounts receivables grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from +21.8% toward the trailing-twelve-month pace of +41.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (36.67M) USD
- Year-over-year change
- -85.0%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (36.67M) | -85.0% |
| FY2024 | 2024-12-31 | (19.82M) | +79.5% |
| FY2023 | 2023-12-31 | (96.88M) | -34.2% |
| FY2022 | 2022-12-31 | (72.2M) | -393.1% |
| FY2021 | 2021-12-31 | (14.64M) | — |
Accounts Receivables vs competitors
How PRVA compares with its peers on the latest reported figures
- PRVA's LTM Jun 2026 accounts receivables of $87.55M is the largest of the 10 companies compared; the peer median is $3.67M.
- Its year-over-year change of +41.1% is the 8th highest of 9, against a peer median of +184.6%.
- Accounts receivables amounts to 3.7% of revenue for PRVA, versus a peer median of 1.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $87.55M | +41.1% | -20.2% | 3.7% | |
| LTM Mar 2026 | $85.22M | +3185.5% | — | 4.5% | |
| LTM Mar 2026 | $19.4M | +209.1% | — | 0.8% | |
| LTM Mar 2026 | $12.07M | +71.3% | +46.5% | 4.3% | |
| LTM Mar 2026 | $9.9M | +307.0% | — | 4.2% | |
| LTM Apr 2026 | $6.91M | +177.6% | -3.0% | 1.4% | |
| LTM Mar 2026 | $3.67M | +163.3% | — | 1.2% | |
| LTM Mar 2026 | $1.17M | +191.7% | -42.5% | 0.9% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | -100.0% | -40.5% | 0.0% | |
| Peer median (excluding PRVA) | $3.67M | +184.6% | -21.8% | 1.2% | |
Competitors are the stored peer set for PRVA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (190.65M) | (12.06M) | 23.08M | 14.39M | 22.92M |
| Depreciation & Amortization | 2.46M | 4.57M | 6.53M | 7.27M | 9.91M |
| Deferred Income Tax | (28.41M) | (7M) | 7.47M | 8.82M | 10.87M |
| Stock-Based Compensation | 253.53M | 67.36M | 0 | 0 | 0 |
| Change in Working Capital | 17.97M | (6.35M) | 8.66M | 19.47M | 44.29M |
| Accounts Receivables | (14.64M) | (72.2M) | (96.88M) | (19.82M) | (36.67M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 6.85M | 118.36M | 52.85M | 14.82M |
| Other Working Capital | 32.61M | 59M | (12.82M) | (13.55M) | 66.14M |
| Other Non-Cash Items | 157K | 687K | 35.05M | 59.34M | 75.42M |
| Operating Cash Flow | 55.06M | 47.2M | 80.79M | 109.28M | 163.4M |
| Capital Expenditures | (547K) | (104K) | (113K) | (5.02M) | (1.2M) |
| Acquisitions (Net) | (32.23M) | 125K | (47.89M) | (5.3M) | (181.72M) |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | (125K) | 0 | 0 | 1.35M |
| Investing Cash Flow | (32.78M) | (104K) | (48.01M) | (10.33M) | (181.57M) |
| Debt Repayment | (875K) | (33.25M) | 0 | 0 | (2.46M) |
| Common Stock Issued | 223.69M | 13.45M | 8.74M | 2.68M | 8.05M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (9.15M) | 125K | 0 | 0 | 1.11M |
| Financing Cash Flow | 213.66M | (19.68M) | 8.74M | 2.68M | 6.7M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 235.94M | 27.42M | 41.52M | 101.64M | (11.46M) |
| Free Cash Flow | 54.51M | 47.09M | 80.67M | 104.26M | 162.2M |
Privia Health Group, Inc.
NASDAQ:PRVA
Intrinsic Alpha fair value
Locked
Current Price
$24.60
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.